Ferrous Succinate

Summary

Ferrous Succinate (CHEMBL3707232) is a phase-3 clinical-stage small molecule (ATC B03AA06); indicated across 1 condition including anemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: B03AA06
• Indications: 1 condition
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707232
Name	Ferrous Succinate
Type	Small molecule
Max phase	3
ATC	B03AA06

Also known as: CEREVON, Ferrlecit 2, Ferromyn, Ferrous succinate, Iron succinate (fe(o4c4h4)), FERROUS SUCCINATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
anemia	4	MONDO:0002280	EFO:0004272

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05714007	PHASE4	RECRUITING	The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery
NCT06830941	PHASE4	NOT_YET_RECRUITING	Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients
NCT02631668	PHASE4	COMPLETED	the Efficacy and Safety of Vitamin C for Iron Supplementation in Adult IDA Patients
NCT05784870	PHASE3	UNKNOWN	A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors
NCT03891277	PHASE2	UNKNOWN	Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).